In this paper, we present a strategy for engineering CD34+ cells to derive mDCs, overexpressing CD93, CD40L, and CXCL13, followed by antigen pulsing for enhanced targeting of pancreatic tumors. This evidence concerns the gene CD40LG and pancreatic neoplasm.